ALLO

Allogene Therapeutics Inc

Apr 09 • 04:00PM ET

2.91

+0.21 7.78 %

Healthcare • Biotechnology • USA • NASD

Peers: NTLA CRSP EDIT BEAM FDMT IOBT SGMO CLLS DTIL CYTK

| Held by: XBI VTI IWM VXF IWN IBB SCHA VTWO PRFZ VHT

Index	RUT	P/E	-	EPS (ttm)	-0.87	Insider Own	33.47%	Shs Outstand	229.41M	Perf Week	13.67%
Market Cap	709.39M	Forward P/E	-	EPS next Y	-0.79	Insider Trans	-0.39%	Shs Float	162.20M	Perf Month	7.38%
Enterprise Value	542.43M	PEG	-	EPS next Q	-0.19	Inst Own	45.64%	Short Float	15.06%	Perf Quarter	95.30%
Income	-190.89M	P/S	-	EPS this Y	7.78%	Inst Trans	1.34%	Short Ratio	4.10	Perf Half Y	115.56%
Sales	0.00M	P/B	2.28	EPS next Y	1.50%	ROA	-39.58%	Short Interest	24.42M	Perf YTD	112.41%
Book/sh	1.28	P/C	2.84	EPS next 5Y	6.94%	ROE	-53.42%	52W High	2.82 3.19%	Perf Year	104.93%
Cash/sh	1.03	P/FCF	-	EPS past 3/5Y	28.61% 16.08%	ROIC	-51.93%	52W Low	0.86 237.55%	Perf 3Y	-40.49%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.20% 9.62%	Perf 5Y	-91.13%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	34.97%	Oper. Margin	-	ATR (14)	0.22	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	7.93	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	65.11	Recom	1.54
Dividend Gr. 3/5Y	- -	Current Ratio	7.93	EPS Q/Q	39.67%	SMA20	20.75%	Beta	0.61	Target Price	7.36
Payout	-	Debt/Eq	0.28	Sales Q/Q	-	SMA50	30.56%	Rel Volume	0.82	Prev Close	2.70
Employees	152	LT Debt/Eq	0.26	Earnings	Mar 12 AMC	SMA200	90.91%	Avg Volume	5.95M	Price	2.91
IPO	Oct 11, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	24.61% -100.00%	Trades		Volume	4,852,374	Change	7.78%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-09-26	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform	$5
Oct-10-25	Downgrade	JP Morgan	Neutral → Underweight
May-14-25	Downgrade	Citizens JMP	Mkt Outperform → Mkt Perform
Mar-14-25	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform	$5
Aug-08-24	Resumed	Oppenheimer	Outperform	$13 → $11
May-31-24	Initiated	Piper Sandler	Overweight	$11
Jan-05-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jan-05-24	Downgrade	Guggenheim	Buy → Neutral
Dec-08-23	Initiated	Citigroup	Buy	$7
Dec-08-23	Initiated	Citigroup	Buy
Jun-26-23	Resumed	Oppenheimer	Outperform	$28
Mar-21-23	Initiated	Bernstein	Mkt Perform	$6
Jan-24-23	Upgrade	JP Morgan	Neutral → Overweight	$20 → $11
Jan-06-23	Upgrade	Robert W. Baird	Neutral → Outperform	$12
Dec-12-22	Downgrade	BofA Securities	Buy → Underperform	$24 → $9
Aug-10-22	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-15-22	Upgrade	Goldman	Neutral → Buy	$9 → $32
Jun-03-22	Initiated	Robert W. Baird	Neutral	$11
Feb-28-22	Reiterated	B. Riley Securities	Buy	$30 → $21
Oct-20-21	Initiated	Cowen	Outperform

Show Previous Ratings

Mar-13-26 08:30AM	Allogene Therapeutics, Inc. Q4 2025 Earnings Call Summary (Moby)
Mar-12-26 11:03PM	Allogene Therapeutics Inc (ALLO) Q4 2025 Earnings Call Highlights: Financial Stability and ... (GuruFocus.com) -6.08%
04:13PM	Allogene Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:02PM	Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update (GlobeNewswire)
Mar-09-26 09:00AM	Take the Zacks Approach to Beat the Markets: Starbucks, Amgen, Allogene in Focus (Zacks) +8.70%
10:34PM	Loading…
Mar-03-26 10:34PM	Allogene Therapeutics Teases April ALPHA3 Futility Data, Details Autoimmune CAR-T Program at TD Cowen (MarketBeat)
Mar-02-26 08:30AM	Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update (GlobeNewswire)
Feb-26-26 11:44AM	Viatris Q4 EPS Tops, Brands Drive Revenue Growth, Stock Up (Zacks) +7.91%
10:54AM	ADMA Q4 EPS Up 14% Y/Y, Revenues Gain From Strong Asceniv Performance (Zacks)
Feb-18-26 07:00PM	Allogene Therapeutics Teases April ALPHA3 Data as cema-cel Targets MRD+ LBCL in Remission (MarketBeat) +5.09% -6.17%
Feb-11-26 09:40AM	Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year? (Zacks)
Feb-05-26 08:30AM	Allogene Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire) -9.44%
07:58AM	Rapid Innovation is Reshaping Oncology: Stocks in Focus (Zacks)
Jan-26-26 09:40AM	Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year? (Zacks) -12.21%
Jan-09-26 09:40AM	Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year? (Zacks) +14.77%
08:30AM	Loading…
Jan-08-26 08:30AM	Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T (GlobeNewswire)
Dec-15-25 05:39PM	Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis (GlobeNewswire)
Nov-10-25 08:30AM	Allogene Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Nov-07-25 11:20AM	Allogene Posts Narrower-Than-Expected Loss in Q3, Nil Sales (Zacks) +12.38%
12:11AM	Allogene Therapeutics Inc (ALLO) Q3 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Nov-06-25 04:26PM	Allogene Therapeutics: Q3 Earnings Snapshot (Associated Press Finance) -5.41%
04:05PM	Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update (GlobeNewswire)
Nov-03-25 09:04AM	Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting (GlobeNewswire)
Oct-30-25 08:30AM	Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update (GlobeNewswire)
Oct-14-25 11:24AM	TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals (Zacks)
Oct-13-25 01:06PM	Zoetis Gains CVMP Backing for Lenivia, Eyes EU Approval in Dog OA Pain (Zacks)
10:15AM	TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder (Zacks)
Oct-10-25 12:21PM	CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza (Zacks) -18.54%
10:27AM	OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data (Zacks)
Oct-08-25 11:18AM	KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure (Zacks) +8.89%
11:15AM	Loading…
11:15AM	AstraZeneca's Baxdrostat Meets Goal in Resistant Hypertension Study (Zacks)
Oct-07-25 11:56AM	MRK Expands Tulisokibart Program in Three New Inflammatory Diseases (Zacks)
Sep-16-25 12:54PM	Krystal Biotech Stock Up on FDA Nod to Vyjuvek Label Update (Zacks)
Sep-12-25 11:30AM	Why Is Allogene Therapeutics (ALLO) Up 9.4% Since Last Earnings Report? (Zacks)
Sep-08-25 09:42AM	Investing in Oncology: 3 Cancer Stocks With Promising Pipelines (Zacks)
Sep-05-25 11:00AM	AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA (Zacks)
10:04AM	AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia (Zacks)
Aug-27-25 08:30AM	Allogene Therapeutics Announces Participation in Upcoming Investor Conference (GlobeNewswire)
Aug-14-25 11:11AM	Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
03:15AM	Allogene Therapeutics Inc (ALLO) Q2 2025 Earnings Call Highlights: Strategic Advancements Amid ... (GuruFocus.com)
Aug-13-25 04:12PM	Allogene Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update (GlobeNewswire)
Aug-12-25 09:34AM	Allogene Therapeutics Inc (ALLO) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Aug-06-25 08:30AM	Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update (GlobeNewswire) -5.36%
Aug-01-25 08:30AM	Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma (GlobeNewswire) -12.20%
07:10AM	Regeneron cancer bispecific rejected again; Allogene discloses trial death (BioPharma Dive)
Jul-23-25 09:26AM	High-Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds (PR Newswire) +16.90%
Jul-21-25 09:41AM	Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025 (Zacks) +5.60%
Jun-12-25 11:30AM	Why Is Allogene Therapeutics (ALLO) Up 52.2% Since Last Earnings Report? (Zacks)
Jun-04-25 12:00PM	All You Need to Know About Allogene Therapeutics (ALLO) Rating Upgrade to Buy (Zacks)
Jun-01-25 10:45AM	Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO (GlobeNewswire)
May-23-25 08:30AM	Allogene Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
May-22-25 05:17PM	Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel (GlobeNewswire)
May-20-25 09:11AM	REGN Signs $256M Buyout Deal With 23andMe to Boost Genomics Research (Zacks) +6.42%
May-16-25 06:36AM	Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff (BioPharma Dive)
May-15-25 11:04AM	Kodiak Q1 Loss Wider Than Expected, Pipeline Development in Focus (Zacks) +14.40%
09:43AM	Allogene (ALLO) Sinks 16% on Downgrade, Trial Delays (GuruFocus.com)
09:35AM	Allogene Therapeutics (ALLO) Loses -31.94% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
May-14-25 11:41AM	Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus (Zacks) -15.68%
10:46AM	Q1 2025 Allogene Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
09:00AM	EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top Line (Zacks)
06:29AM	Allogene's Q1 Earnings In Line With Estimates, Sales Nil (Zacks)
03:18AM	Allogene Therapeutics Inc (ALLO) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
May-13-25 04:11PM	Allogene Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update (GlobeNewswire)
12:07PM	Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus (Zacks)
08:42AM	Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y (Zacks)
May-12-25 09:40AM	Allogene Therapeutics Inc (ALLO) Q1 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
09:20AM	RDY Q4 Earnings Beat Estimates, Generics Revenues Rise Y/Y, Stock Up (Zacks)
May-09-25 08:26AM	Is Allogene Therapeutics, Inc. (ALLO) the Low Risk High Reward Stock Set to Triple by 2030? (Insider Monkey)
May-06-25 08:30AM	Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update (GlobeNewswire) -20.99%
Apr-23-25 10:12AM	Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-08-25 06:46AM	FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug (Zacks)
Apr-07-25 08:30AM	Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma (GlobeNewswire)
Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
Mar-14-25 03:00PM	Allogene Therapeutics Inc (ALLO) Q4 2024 Earnings Call Highlights: Financial Challenges Amid ... (GuruFocus.com)
Mar-13-25 04:11PM	Allogene Therapeutics: Q4 Earnings Snapshot (Associated Press Finance) -8.25%
04:02PM	Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update (GlobeNewswire)
Mar-03-25 08:30AM	Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update (GlobeNewswire) -7.69%
Feb-26-25 08:30AM	Allogene Therapeutics Announces Participation in March Investor Conference (GlobeNewswire)
Feb-25-25 04:10PM	Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia (GlobeNewswire) -7.24%
Feb-13-25 04:30PM	Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology (GlobeNewswire) +44.68%
Feb-04-25 08:30AM	Allogene Therapeutics Announces Participation in February Investor Conferences (GlobeNewswire)
Jan-29-25 08:30AM	Allogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical Officer (GlobeNewswire)
Jan-28-25 08:30AM	Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases (GlobeNewswire)
Dec-26-24 12:00PM	Allogene Therapeutics (ALLO) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
11:26AM	Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment (PR Newswire)
Dec-16-24 08:30AM	Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +8.99%
Dec-12-24 08:30AM	Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman (GlobeNewswire) -5.61%
Nov-25-24 12:00PM	Allogene Therapeutics (ALLO) Upgraded to Buy: Here's Why (Zacks)
Nov-19-24 08:30AM	Allogene Therapeutics Announces Participation in December Investor Conferences (GlobeNewswire)
Nov-18-24 08:30AM	Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence (GlobeNewswire) -5.29%
Nov-08-24 06:07AM	Allogene Therapeutics Inc (ALLO) Q3 2024 Earnings Call Highlights: Financial Resilience Amidst ... (GuruFocus.com)
Nov-07-24 04:11PM	Allogene Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:02PM	Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update (GlobeNewswire)
10:00AM	Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS (GlobeNewswire)
Nov-06-24 07:31AM	Allogene Therapeutics Inc (ALLO) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com) +7.69%
Nov-05-24 09:10AM	Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Nov-04-24 08:30AM	Allogene Therapeutics Announces Participation in November Investor Conferences (GlobeNewswire) +10.29%
Oct-31-24 10:01AM	Will Allogene Therapeutics (ALLO) Report Negative Earnings Next Week? What You Should Know (Zacks)

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Beneski Benjamin Machinas	SVP, Chief Technical Officer	Mar 31 '26	Sale	2.50	2,867	7,168	195,338	Apr 02 04:47 PM
Beneski Benjamin Machinas	Officer	Apr 01 '26	Proposed Sale	2.50	2,867	7,168		Apr 01 07:13 PM
Beneski Benjamin Machinas	SVP, Chief Technical Officer	Mar 16 '26	Sale	2.47	4,835	11,942	198,205	Mar 18 04:06 PM
Chang David D	President and CEO	Mar 16 '26	Sale	2.47	47,763	117,975	5,150,599	Mar 18 04:05 PM
Beneski Benjamin Machinas	Officer	Mar 16 '26	Proposed Sale	2.47	4,835	11,928		Mar 16 08:20 PM
Chang David D	Officer	Mar 16 '26	Proposed Sale	2.47	47,763	117,827		Mar 16 08:05 PM
Beneski Benjamin Machinas	SVP, Chief Technical Officer	Mar 02 '26	Sale	2.60	7,132	18,543	203,040	Mar 04 05:42 PM
Beneski Benjamin Machinas	Officer	Mar 02 '26	Proposed Sale	2.60	7,132	18,541		Mar 02 09:04 PM
Beneski Benjamin Machinas	SVP, Chief Technical Officer	Feb 02 '26	Sale	1.73	7,549	13,060	210,172	Feb 04 05:20 PM
Chang David D	President and CEO	Feb 02 '26	Sale	1.80	95,269	171,484	5,185,862	Feb 04 05:18 PM
Parker Geoffrey M.	CHIEF FINANCIAL OFFICER	Feb 02 '26	Sale	1.76	24,001	42,242	1,252,795	Feb 04 05:16 PM
Douglas Earl Martin	SVP, General Counsel	Feb 02 '26	Sale	1.76	22,900	40,304	564,948	Feb 04 05:12 PM
Yoshiyama Annie	SVP, Finance	Feb 02 '26	Sale	1.72	4,167	7,167	130,322	Feb 04 05:09 PM
Roberts Zachary	EVP of R&D	Feb 02 '26	Sale	1.77	35,700	63,189	581,166	Feb 04 05:07 PM
EARL DOUGLAS	Officer	Feb 02 '26	Proposed Sale	1.76	22,900	40,215		Feb 02 05:17 PM
GEOFFREY M PARKER	Officer	Feb 02 '26	Proposed Sale	1.76	24,001	42,189		Feb 02 05:16 PM
ZACHARY J ROBERTS	Officer	Feb 02 '26	Proposed Sale	1.77	35,700	63,353		Feb 02 05:16 PM
ANNIE T YOSHIYAMA	Officer	Feb 02 '26	Proposed Sale	1.72	4,167	7,178		Feb 02 05:15 PM
DAVID CHANG	Officer	Feb 02 '26	Proposed Sale	1.80	243,976	438,522		Feb 02 04:51 PM
BENJAMIN M BENESKI	Officer	Feb 02 '26	Proposed Sale	1.73	16,823	29,052		Feb 02 04:49 PM
Roberts Zachary	EVP of R&D	Jan 21 '26	Sale	1.56	26,269	40,980	616,866	Jan 23 04:15 PM
Roberts Zachary	Officer	Jan 21 '26	Proposed Sale	1.56	26,269	40,929		Jan 21 07:53 PM
Kazam Joshua A	Director	Dec 18 '25	Option Exercise	0.00	47,700	0	350,763	Dec 22 06:57 PM
Beneski Benjamin Machinas	SVP, Chief Technical Officer	Nov 17 '25	Sale	1.22	786	959	217,721	Nov 19 04:09 PM
Beneski Benjamin Machinas	Officer	Nov 17 '25	Proposed Sale	1.22	786	959		Nov 17 07:14 PM
Parker Geoffrey M.	CHIEF FINANCIAL OFFICER	Oct 21 '25	Sale	1.26	36,744	46,169	1,276,796	Oct 23 06:20 PM
Parker Geoffrey M.	Officer	Oct 21 '25	Proposed Sale	1.26	36,744	46,169		Oct 21 08:52 PM
MESSEMER DEBORAH M.	Director	Jun 10 '25	Sale	1.42	36,885	52,377	107,431	Jun 12 04:18 PM
MESSEMER DEBORAH M.	Director	Jun 10 '25	Proposed Sale	1.42	36,885	52,391		Jun 10 04:29 PM
Yoshiyama Annie	SVP, Finance	Apr 21 '25	Sale	1.41	9,601	13,537	130,663	Apr 23 05:28 PM
Yoshiyama Annie	Officer	Apr 21 '25	Proposed Sale	1.41	9,601	13,537		Apr 21 04:49 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALLO

Allogene Therapeutics Inc

Upgrade your Finviz experience